Literature DB >> 24889769

Chemotherapy: NEPA-a single oral dose providing effective prevention of chemotherapy-induced nausea and vomiting.

Alessia Errico.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24889769     DOI： 10.1038/nrclinonc.2014.92

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  3 in total

1.  Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study.

Authors:  P J Hesketh; G Rossi; G Rizzi; M Palmas; A Alyasova; I Bondarenko; A Lisyanskaya; R J Gralla
Journal:  Ann Oncol       Date:  2014-03-07       Impact factor: 32.976

2.  A phase III study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapy.

Authors:  R J Gralla; S M Bosnjak; A Hontsa; C Balser; G Rizzi; G Rossi; M E Borroni; K Jordan
Journal:  Ann Oncol       Date:  2014-03-14       Impact factor: 32.976

3.  A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy.

Authors:  M Aapro; H Rugo; G Rossi; G Rizzi; M E Borroni; I Bondarenko; T Sarosiek; C Oprean; S Cardona-Huerta; V Lorusso; M Karthaus; L Schwartzberg; S Grunberg
Journal:  Ann Oncol       Date:  2014-03-05       Impact factor: 32.976
  3 in total
  2 in total

Review 1.  Management of chemotherapy-induced nausea and vomiting by risk profile: role of netupitant/palonosetron.

Authors:  Vito Lorusso
Journal:  Ther Clin Risk Manag       Date:  2016-06-07       Impact factor: 2.423

Review 2.  Management of acute and delayed chemotherapy-induced nausea and vomiting: role of netupitant-palonosetron combination.

Authors:  Piotr K Janicki
Journal:  Ther Clin Risk Manag       Date:  2016-05-02       Impact factor: 2.423
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.